Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Artificial Intelligence in Drug Discovery: Resources, Methods, and Applications

Dunash ben Labrat

The field of drug discovery is constantly seeking innovative approaches to overcome the challenges associated with developing new therapeutics. Artificial Intelligence (AI) has emerged as a transformative technology with the potential to revolutionize the drug discovery process. This abstract provides an overview of the resources, methods, and applications of AI in drug discovery. It highlights the role of AI in addressing the complexities and costs of drug development, while emphasizing its potential to accelerate the identification of novel therapeutic targets and optimize lead compounds. The abstract also discusses the use of AI in clinical trial optimization and drug repurposing, demonstrating its versatility in different stages of the drug discovery pipeline. Additionally, it explores the challenges and limitations of AI, such as ethical considerations and regulatory hurdles, and offers insights into future directions and implications. Overall, this abstract highlights the significant impact of AI in drug discovery and its potential to transform the pharmaceutical industry by improving efficiency, accuracy, and success rates in the development of new treatments.